Jason Lettmann, Lightstone Ventures

Light­stone Ven­tures un­veils $375M third fund, this time ex­pand­ing its wish­list in blos­som­ing CNS field

Neu­ro­science is hav­ing a mo­ment right now, and one VC firm strad­dling the line be­tween biotech and medtech is look­ing to cap­i­tal­ize on the field’s rapid growth.

Light­stone Ven­tures has raised $375 mil­lion for its third ven­ture fund with an eye on ex­pand­ing its fo­cus in CNS dis­ease, the firm said Tues­day.

The newest raise brings Light­stone’s to­tal to more than $850 mil­lion since the firm was found­ed back in 2012. So far, that trea­sure chest has led to in­vest­ments in around 30 com­pa­nies split across the biotech and medtech spaces. With its third and largest fund, Light­stone is ex­pect­ing much the same as be­fore — most­ly in­vest­ments in seed-stage to Se­ries A com­pa­nies with an eye on “break­throughs” in pa­tient care, gen­er­al part­ner Ja­son Lettmann told End­points News.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.